RecruitingNot ApplicableNCT05833217

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2 Infection and Inflammation in Human Adipose Tissue


Sponsor

Stanford University

Enrollment

55 participants

Start Date

Jun 6, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir for SARS-CoV-2 persistence. The results will not only determine whether obesity and IR are risk factors for PASC, but will also define fundamental biology that sets the stage for the investigation of novel or existing therapies that target the causal pathways identified.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria3

  • Ages 18 to 80
  • BMI ≥ 25 kg/m2
  • not currently pregnant

Exclusion Criteria19

  • Arm 2 (Adipose Tissue Biopsy) exclusions include
  • pregnancy
  • prior liposuction
  • recent change in weight (> 2 kg in one month)
  • bleeding disorders
  • anticoagulant use
  • Arm 3 (healthy controls only) exclusions include patients with
  • major organ disease
  • diabetes
  • history of liposuction
  • bariatric surgery
  • eating disorders
  • psychiatric disorders
  • pregnancy or lactation
  • recent change in weight (over the past 12 weeks),
  • use of weight loss medication or oral steroids
  • hematocrit < 33%
  • fasting glucose >= 126 mg/dL
  • blood pressure >160/100 mmHg

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREAdipose Tissue Biopsy

After an overnight fast, approximately 1-2 grams of subcutaneous fat will be removed by a needle. Participants will have a local anesthetic prior to the procedure. The needle fat biopsy will be repeated at quarterly intervals for one year (every 3 months). We will also draw 1 10mL tube of blood at each biopsy for measurement of inflammatory cytokines.

DIAGNOSTIC_TESTSteady State Plasma Glucose (SSPG) Test

An Insulin Sensitivity Test (SSPG: Steady State Plasma Glucose) is performed to determine if participants are insulin sensitive or insulin resistant. This test is approximately 5-6 hours in length. Participants will be asked to fast for 12 hours. The insulin sensitivity test is designed to measure how well your cells remove glucose from your blood in response to insulin. During this test participants will have two small catheters (tubing) placed in their veins (I.V. lines). The total amount of blood that will be drawn during this test will be 140 mL of blood (approximately 9.5 tablespoons). Insulin is a natural hormone, and octreotide (a synthetic hormone) is a drug that temporarily blocks the secretion of insulin from your pancreas. A member of the research team is present and monitoring the results along with the nursing staff.


Locations(2)

Clinical and Translational Research Unit

Palo Alto, California, United States

Stanford Health

Palo Alto, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05833217


Related Trials